Intellia Therapeutics Financials
| NTLA Stock | USD 9.00 0.30 3.45% |
Intellia |
Please note, the presentation of Intellia Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Intellia Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Intellia Therapeutics' management manipulating its earnings.
Intellia Therapeutics Stock Summary
Intellia Therapeutics competes with Editas Medicine, Caribou Biosciences, Crispr Therapeutics, Verve Therapeutics, and Beam Therapeutics. Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Intellia Thera operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 485 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US45826J1051 |
| CUSIP | 45826J105 |
| Location | Massachusetts; U.S.A |
| Business Address | 40 Erie Street, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.intelliatx.com |
| Phone | 857 285 6200 |
| Currency | USD - US Dollar |
Intellia Therapeutics Key Financial Ratios
| Return On Equity | -0.54 | ||||
| Return On Asset | -0.27 | ||||
| Target Price | 43.92 | ||||
| Number Of Employees | 403 | ||||
| Beta | 1.97 |
Intellia Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Intellia Therapeutics's current stock value. Our valuation model uses many indicators to compare Intellia Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Intellia Therapeutics competition to find correlations between indicators driving Intellia Therapeutics's intrinsic value. More Info.Intellia Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Intellia Therapeutics' earnings, one of the primary drivers of an investment's value.Intellia Therapeutics Systematic Risk
Intellia Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Intellia Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Intellia Therapeutics correlated with the market. If Beta is less than 0 Intellia Therapeutics generally moves in the opposite direction as compared to the market. If Intellia Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Intellia Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Intellia Therapeutics is generally in the same direction as the market. If Beta > 1 Intellia Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
About Intellia Therapeutics Financials
What exactly are Intellia Therapeutics Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Intellia Therapeutics' income statement, its balance sheet, and the statement of cash flows. Potential Intellia Therapeutics investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Intellia Therapeutics investors may use each financial statement separately, they are all related. The changes in Intellia Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Intellia Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Intellia Therapeutics March 23, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Intellia Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Intellia Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Intellia Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Intellia Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Intellia Therapeutics's daily price indicators and compare them against related drivers.
| Information Ratio | (0.06) | |||
| Maximum Drawdown | 20.66 | |||
| Value At Risk | (7.09) | |||
| Potential Upside | 7.76 |
Complementary Tools for Intellia Stock analysis
When running Intellia Therapeutics' price analysis, check to measure Intellia Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intellia Therapeutics is operating at the current time. Most of Intellia Therapeutics' value examination focuses on studying past and present price action to predict the probability of Intellia Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intellia Therapeutics' price. Additionally, you may evaluate how the addition of Intellia Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |